Q2 FY2026 EarningsQ2 FY26 beat consensus across top-line metrics: total revenue reached $240.3M vs. $229.8M expected, driven by strong BRIUMVI US sales of $227.7M. Gross margin of 83% was slightly below the 85.0% consensus due to the mix of lower-margin ex-US supply sales to Neuraxpharm. GAAP EPS of $0.05 missed the $0.31 consensus significantly, primarily due to a surge in 'Other R&D' expenses ($87.3M) related to subcutaneous formulation development, which far exceeded normalized quarterly run rates. Operating cash flow of $21.4M (for the six months) turned positive YoY, though it remains tight relative to R&D acceleration.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: TG Therap(TGTX) the Revenue is 240.34 M (+70.27%), Beat estimate;the EBIT is 21.67 M (-37.8%), Miss estimate;the EPS is 0.05 (-70.59%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.24B70.27%
0.23B62.80%
+0.01B7.47%
EBITMiss expectations
0.02B37.80%
0.06B75.98%
-0.04B113.78%
EPSMiss expectations
0.0570.59%
0.306180.06%
-0.2561150.65%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf